TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Pain 24 hours after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to normal daily activities after surgery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fewer cases of influenza caused by virus strains antigenically similar to vaccine
Endpoint domain: Mortality/survival
Primary endpoint: Reduced number of RTI-related healthcare provider visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduced missed days of school, kindergarten, or day care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cumulative probability of parasite qPCR positivity by day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean parasitemia at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deliveries at <34 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Grade III/IV intraventricular hemorrhage (IVH)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in anteversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in hip rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in foot progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Recovery time of SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resistive Index (RI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean Flow Velocities (MFV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Duration of analgesic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to return to full activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fetal heart rate (FHR) interpretation agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Heart failure hospitalization rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Early dyspnoea relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced mortality at Days 14 and 30
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in walking pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric colonization by potentially pathogenic microorganisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Gastric pH values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: symptoms and disability measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: therapist time required
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: LSA-CI composite score sensitivity to change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: clarity-of-vision at intermediate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clarity-of-vision at near
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean thickness of the residual myometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean healing ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients enrolled in hospice care
Endpoint domain: Mortality/survival
Primary endpoint: Mean number of days in hospice
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: elbow, wrist, and finger spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: affected upper extremity real-world arm function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: laboratory motor activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy intake achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypertriglyceridemia development
Endpoint domain: Adverse events/effects
Primary endpoint: Weight for age percentile maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-treatment blood PCR concordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean values of inflammatory cytokines (leptin, TNF-alpha, IL2, IL4, IL6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 24-hour RBC recoveries of 75% or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean hemolysis of less than 0.6%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: no serious or unexpected adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Nonperformance of CDE due to physician decision
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean maximum percentage PNIF fall from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% effective dose of sildenafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum venoconstriction induced by phenylephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sensitivity to nitroglycerin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Insulin-stimulated hepatic glucose uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: day-time symptom scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: day-time SABA use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum endometritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: NRS-max score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual acuity (20/40 or better in at least 1 eye)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy for detection of small bowel CD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy for detection of small bowel stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: redisplacements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horesh score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volar angle deformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radial angle deformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-density lipoprotein (HDL) cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of life improvement (SF-36 scores)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Arterial stiffness improvement (ba-PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total ketobemidone consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death before discharge
Endpoint domain: Mortality/survival
Primary endpoint: severe IVH/PVL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: diastolic function of the left ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Esophageal mucosal/submucosal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates to diary completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Completeness of recording near miss and minor injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: esthetic evaluation by the patient
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: reduction in root hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h glucose infusion rate area under the curve (AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma glucagon levels (AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lipolysis (free fatty acid AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of distant vision of naked eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median minutes of MVPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in free 3HC/COT ratio in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in free 3HC/COT ratio in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic risk markers related to cardiovascular health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: single‐procedure freedom from AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive performance measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Delivered energy at the defibrillation threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PAF‐AH activity elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% reduction in Severity of Alopecia Tool score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-grade improvement in eyelash scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-grade improvement in eyebrow scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of patient-centred care pathway
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percentage of participants free of complaints after one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean societal costs after one year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Probability of cost-effectiveness of postural exercise therapy over physiotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ongoing pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evoked pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean overnight urinary cortisol excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: overnight geometric mean urinary cortisol/creatinine excretion ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum cortisol levels before and after ACTH simulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: visual-analogue pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GH basal levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: GH responsiveness to GHRH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: MENQOL vasomotor function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Selection errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical healing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time of osseous union
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function of knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete plus major response (C+MR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSQI total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: control of force output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sEMG parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemorrhagic stroke rates
Endpoint domain: Mortality/survival
Primary endpoint: Mean percent reduction in ulcer area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total number of detected cerebral microemboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Embolization rates during cardiopulmonary bypass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: postoperative paralytic ileus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: acute Grade 2 and 3 toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Mean daily utility value
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: visual analogue scale scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of carbamazepine (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of distribution of carbamazepine (V/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: increased wheeze
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Morbidity and mortality (modified Rankin Scale>2) at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: New neurological deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hospitalisations beyond 5 days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction in screen-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 h diuresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Tooth colour change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal counts of Lactobacilli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum tyrosine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Behavioral symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neutropenia ≥grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: B(max) density of clearance receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infiltration pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative proportion of persons with CrCl <60 mL/min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cost of achieving minimally important clinical difference (MID) in OHrQOL
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of activity sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pad usage rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urine leakage weights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved wall motion in scar segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systolic fractional thickening in scar segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total charges
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: post-surgical complications
Endpoint domain: Adverse events/effects
Primary endpoint: radiographic nonprogression criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean changes in mTSS, erosion, and joint space narrowing scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HVLT-R total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIQ score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-minute walk test increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hours of physical activity increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotection rates (SPR, anti‐HBs titer ≥10 mIU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean itching score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: redness of the conjunctiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Agreement between assessments of habitual fit fluorescein patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability and validity of fluorescein pattern assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: overall judgment accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decision-making errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sedentary behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary antioxidant capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average pain scores the day after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adipocyte volume/tissue volume (AV/TV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adipocyte number (Ad#)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of advanced AMD progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Glutamate release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cutaneous blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean preoperative Constant score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of intact cuffs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean passive external rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure Pain Tolerance (PPTOL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: iliofemoral patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: venous obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: S-100beta levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Shuttle walking test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute cooling rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: voice function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vocal health improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vocal communication improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization-free survival at 18 months
Endpoint domain: Mortality/survival
Primary endpoint: combined death or severe adverse neurodevelopmental outcome
Endpoint domain: Mortality/survival
Primary endpoint: Recognition of fear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary artery disease score (CAD score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Seropositive rates of IgG antibodies against C. pneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seropositive rates of IgA antibodies against C. pneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: DPP-4 inhibition over 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUC of plasma insulin over 2 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Local tumor control rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes